Womack Financial LLC Invests $1.15 Million in Medpace Holdings, Inc. $MEDP

Key Points

• Womack Financial initiated a Medpace position worth approximately $1.15 million, while other institutional investors also made sizable purchases; institutions now own 77.98% of the company.
• Medpace reported better-than-expected quarterly results, with EPS of $4.25 and revenue of $707.33 million, up 17.2% year over year. The company guided to fiscal 2026 EPS of $17.25–$17.95.
• Despite strong results, analysts maintain a consensus “Hold” rating with an average price target of $584.18, below the stock’s reported $620.03 price; insiders have sold roughly $73.9 million in shares over the past three months.

Womack Financial LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,175 shares of the company's stock, valued at approximately $1,152,000. Medpace comprises 0.8% of Womack Financial LLC's portfolio, making the stock its 24th biggest position.

Other large investors also recently bought and sold shares of the company. Ranger Investment Management L.P. acquired a new position in shares of Medpace during the 2nd quarter worth approximately $14,230,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Medpace in the second quarter valued at approximately $2,134,000. Sanctuary Advisors LLC acquired a new stake in shares of Medpace in the second quarter valued at approximately $1,486,000. Solstein Capital LLC purchased a new position in Medpace during the second quarter worth approximately $35,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Medpace during the second quarter worth approximately $58,442,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

Insider Buying and Selling at Medpace

In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the sale, the director directly owned 3,798 shares of the company's stock, valued at $2,302,157.70. This represents a 65.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 27,174 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the sale, the chief executive officer owned 561,195 shares in the company, valued at approximately $347,261,854.05. This trade represents a 4.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 125,661 shares of company stock valued at $73,854,945. Corporate insiders own 20.50% of the company's stock.

Medpace Trading Down 0.1%

Shares of NASDAQ MEDP opened at $620.03 on Tuesday. The stock has a market capitalization of $17.31 billion, a PE ratio of 36.34, a PEG ratio of 2.77 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The stock has a fifty day simple moving average of $553.21 and a 200-day simple moving average of $492.40.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the prior year, the company earned $3.10 EPS. Medpace's revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MEDP shares. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Jefferies Financial Group lowered Medpace from a "buy" rating to a "hold" rating and lifted their price target for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Robert W. Baird boosted their price target on shares of Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a research report on Friday, July 24th. Truist Financial upped their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a report on Friday, July 24th. Finally, TD Cowen raised their price objective on shares of Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $584.18.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source